Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. is headquartered in Austin, Texas.
IPO Year: 2005
Exchange: NASDAQ
Website: mtem.com
BofA Securities initiated coverage of Molecular Templates with a rating of Buy and set a new price target of $12.00
UBS initiated coverage of Molecular Templates with a rating of Neutral and set a new price target of $13.00
4 - Molecular Templates, Inc. (0001183765) (Issuer)
AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023. Dr. Voi joins MTEM from Novartis, where he served as Vice President, Global Program Head, for the PD-1 antibody Tislelizumab since April 2021. He was previously Global Program Head, Melanoma, at Novartis, a pos
Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General Counsel AUSTIN, Texas, March 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or "the Company"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the appointment of Gabriela Gruia, M.D., to its Board of Directors and the promotion of Megan Filoon to General Counsel. "Dr. Gruia brings a wealth of industry knowledge to our Board of Directors," said Barry Selick, Ph.D., Chairman of the Board of Molecular
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders' established experience in global clinical development and especially with new technologies will be instrumental as we further advance our ongoing clinical trials and continue to expand our rare disease pipeline of novel therapeut
SC 13D/A - Molecular Templates, Inc. (0001183765) (Subject)
SC 13D/A - Molecular Templates, Inc. (0001183765) (Subject)
SC 13G - Molecular Templates, Inc. (0001183765) (Subject)
SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)
SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)
SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)
SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)
SC 13D/A - Molecular Templates, Inc. (0001183765) (Subject)
SC 13G - Molecular Templates, Inc. (0001183765) (Subject)
SC 13G - Molecular Templates, Inc. (0001183765) (Subject)
Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) programEarly indication of monotherapy activity in CTLA-4 ETB (MT-8421) program through T-reg depletion; no drug-related adverse events > grade 2Novel mechanism of action targeting CD38+ immune cells of B-cell, T-cell, and monocytic lineage representing enhanced potency in I&I without the need for conditioning therapy AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development o
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases. AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or "ETBs") for cancer and immune-mediated disease, today provided an update on its clinical-stage programs. Eric Poma, PhD., Chief Executive and Chief Scientific O
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ("ETBs"), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024. Recent Company Highlights MTEM presented clinical data at the 2024 AACR Annual Meeting that demonstrated MT-6402's tolerable safety and promising efficacy profile in relapsed/refractory HNSCC patients. As monotherapy in 7 evaluable HNSCC patient
AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ("ETBs"), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced that MTEM will present a poster, "First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim Data," at the 2024 American Association for Cancer Research Annual
AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ("ETBs"), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023. Company Highlights Durable single agent activity observed with MT-6402, a PD-L1 targeting direct-cell kill agent, in heavily pre-treated patients with low PD-L1+ head and neck cancer who had progressed on multiple prior th
AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced today it has entered into a definitive amended and restated securities purchase agreement with certain healthcare investors that will provide $9.5 million in gross proceeds to MTEM through the closing of the second tranche of its previously announced July 2023 private placement and purchase agreement on
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ("ETBs"), to create novel therapies with potent differentiated mechanisms of action for cancer, today provided an update on its programs. Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, "ETBs represent a new approach to oncology drug development that continue to show unique biology and monotherapy activity in heavily pre-treated patients. We are particularly excited about the mono
AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference. Oppenheimer 34rd Annual Healthcare Conference, February 13 – 14 Format: Virtual PresentationDate: Wednesday, February 14, 2024Time: 9:20 – 9:50am Eastern TimeWebcast access: The live-streamed webcast can be accessed here Presentation links can be found in the "News and Media" section of the corporate website. One-on-one
AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ("ETBs"), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the third quarter of 2023. Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, "ETBs represent a new approach to oncology drug development that continue to show unique biology and monotherapy activity in heavily pre-treated patients.
AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors. The Phase 1 study is a multi-center open-label, dose-escalation, dose-expansion, and a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary efficacy of MT-842
4 - Molecular Templates, Inc. (0001183765) (Issuer)
4 - Molecular Templates, Inc. (0001183765) (Issuer)
4 - Molecular Templates, Inc. (0001183765) (Issuer)
4 - Molecular Templates, Inc. (0001183765) (Issuer)
4 - Molecular Templates, Inc. (0001183765) (Issuer)
4 - Molecular Templates, Inc. (0001183765) (Issuer)
4 - Molecular Templates, Inc. (0001183765) (Issuer)
4 - Molecular Templates, Inc. (0001183765) (Issuer)
4 - Molecular Templates, Inc. (0001183765) (Issuer)
4 - Molecular Templates, Inc. (0001183765) (Issuer)
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients. Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases.
Molecular Templates (NASDAQ:MTEM) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.78) by 110.26 percent. The company reported quarterly sales of $11.09 million which beat the analyst consensus estimate of $5.90 million by 87.99 percent. This is a 69.73 percent decrease over sales of $36.63 million the same period last year.
- SEC Filing
-SEC Filing
Gainers Jaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $1.9. The company's market cap stands at $128.7 million. Corvus Pharma (NASDAQ:CRVS) shares increased by 7.36% to $1.75. The market value of their outstanding shares is at $85.8 million. ImmuCell (NASDAQ:ICCC) shares increased by 7.27% to $5.6. The market value of their outstanding shares is at $43.4 million. Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 6.46% to $0.16. The company's market cap stands at $6.9 million. Xilio Therapeutics (NASDAQ:XLO) shares increased by 5.34% to
Molecular Templates, Inc (NASDAQ:MTEM) shares are volatile Tuesday after the company presented interim data from MT-6402 Phase I study in patients with PD-L1+ solid tumors. The Details: Molecular Templates said the findings show that MT-6402 acts uniquely from other approved checkpoint agents and was well-tolerated with no drug-related Grade 4 or Grade 5 adverse events observed. “We are excited to see objective responses in heavily pre-treated, checkpoint-experienced, head and neck cancer patients, a setting with high unmet medical need,” said CEO Eric Poma. “The long-lasting partial responses were in patients with low PD-L1 expression and showed concomitant increases in cytoki
The poster highlighted the following findings from the phase I dose-escalation study of MT-6402:MT-6402 has been well tolerated with no drug-related Grade 4 or Grade 5 adverse events observed MT-6402 acts uniquely from other approved checkpoint agents. MT-6402 depletes immunosuppressive PD-L1+ immune cells and tumor cells, activates a T-effector phenotype, and remodels the tumor microenvironment to restore T-cell surveillance of the tumor. An early monotherapy efficacy signal in head and neck squamous cell carcinoma (HNSCC) was identified. Nine patients with recurrent and metastatic heavily pre-treated and checkpoint-experienced HNSCC were treated in the phase I dose escalation of which two
Gainers Protara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 25.93% to $8.06. The company's market cap stands at $236.5 million. Etao International Co (NASDAQ:ETAO) shares moved upwards by 25.61% to $3.58. The market value of their outstanding shares is at $18.3 million. Indaptus Therapeutics (NASDAQ:INDP) shares rose 11.11% to $2.5. The company's market cap stands at $21.3 million. scPharmaceuticals (NASDAQ:SCPH) stock moved upwards by 10.7% to $5.69. The company's market cap stands at $205.1 million. Molecular
DEF 14A - Molecular Templates, Inc. (0001183765) (Filer)
PRE 14A - Molecular Templates, Inc. (0001183765) (Filer)
8-K - Molecular Templates, Inc. (0001183765) (Filer)
8-K - Molecular Templates, Inc. (0001183765) (Filer)
8-K - Molecular Templates, Inc. (0001183765) (Filer)
10-Q - Molecular Templates, Inc. (0001183765) (Filer)
8-K - Molecular Templates, Inc. (0001183765) (Filer)
DEFA14A - Molecular Templates, Inc. (0001183765) (Filer)
DEF 14A - Molecular Templates, Inc. (0001183765) (Filer)
8-K - Molecular Templates, Inc. (0001183765) (Filer)